Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 June 2025 | Story Tshepo Tsotetsi | Photo Supplied
Dr Herkulaas Combrink
Dr Herkulaas Combrink is representing UFS in a new international research project that aims to improve how evidence is used in public health policymaking.

Dr Herkulaas Combrink, a senior lecturer in the Faculty of Economic and Management Sciences (EMS) at the University of the Free State (UFS), is representing the university in a new international research project that aims to improve how evidence is used in public health policymaking.

Dr Combrink, who is also a co-director of the Interdisciplinary Centre for Digital Futures (ICDF), has been selected as one of the principal investigators in a newly funded project supported by the UK’s International Science Partnerships Fund under the Evidence-Informed Policymaking Programme. Running from April 2025 to March 2026, the project – titled Integrating Evidence for Contextualised Public Health Policy: Lessons from South Africa – explores how different types of evidence can be used more effectively in shaping public health policy. The international collaboration includes researchers from the Centre for Philosophy of Epidemiology, Medicine and Public Health, which is a collaboration between Durham University and the University of Johannesburg; as well as Durham’s Centre for Humanities Engaging Science and Society.

 

From the Free State to global impact

For Dr Combrink, being part of this collaboration highlights the important work being done in the faculty and ICDF that is reaching beyond borders. 

“It’s important to showcase the impact we are making from the Free State that leads to global outcomes,” he said.

The project aims to evaluate an evidence mapping framework to determine how model-based projections and social listening reports can be more effectively integrated and contextualised for policymaking.

“These are two very different data types,” he explained. “The value lies in demonstrating how to apply the framework to different contexts for evidence-based mapping.”

Dr Combrink brings extensive expertise to the team, having worked on both disease modelling and risk communication during South Africa’s COVID-19 response. He was involved in national and provincial social listening initiatives, and used high-frequency social media data to track the spread of misinformation, often referred to as the ‘infodemic.’ 

“We’ve built up enough data within ICDF and EMS to support this study,” he noted.

The goal is not just theoretical. A key outcome of the project is engaging directly with policymakers to refine modelling and risk communication strategies for future pandemics. 

“This will help us to engage with the various departments of health to assist with improving modelling and risk communication work for better social behavioural change,” he explained.

According to Prof Brownhilder Neneh, Vice-Dean for Research and Internationalisation in the EMS faculty, the project reflects the faculty’s growing global presence. 

“Dr Combrink’s participation is a testament to the calibre of scholarship within the faculty,” she said. “It positions EMS as a key contributor to shaping policy and practice with societal impact.”

She added that the collaboration aligns well with the faculty’s vision for global partnerships that are rooted in local relevance.

“By focusing on contextualised evidence for policymaking, this project reflects our commitment to relevance, engagement and global partnership,” she said.

 

What comes next

Over the project’s 12-month timeline, the team will deliver:

• a case study analysis of modelling and social listening during South Africa’s COVID-19 response;
• an extended evidence mapping framework tailored to diverse evidence types;
• policy briefs and practical tools for public health practitioners; and
• a hybrid international workshop in late 2025 bringing together researchers, policymakers and health professionals to test and refine these outputs.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept